Compare · IMAC vs NTRA
IMAC vs NTRA
Side-by-side comparison of IMAC Holdings Inc. (IMAC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMAC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $28.88B, about 847.6x IMAC ($34.1M).
- NTRA has hit the wire 9 times in the past 4 weeks while IMAC has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 1 for IMAC).
- Company
- IMAC Holdings Inc.
- Natera Inc.
- Price
- $1.01+9.76%
- $203.89+1.33%
- Market cap
- $34.1M
- $28.88B
- 1M return
- -
- +3.31%
- 1Y return
- -
- +33.31%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2015
- News (4w)
- 0
- 9
- Recent ratings
- 1
- 25
IMAC Holdings Inc.
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. The company operates 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest IMAC
- SEC Form SC 13G filed by IMAC Holdings Inc.
- SEC Form 10-Q filed by IMAC Holdings Inc.
- SEC Form 4: Sucoff Cary was granted 100,000 shares, increasing direct ownership by 100% to 200,000 units
- SEC Form 4: Evans Maurice E. was granted 100,000 shares, increasing direct ownership by 89% to 212,420 units
- SEC Form 4: Pruitt Michael D was granted 100,000 shares and covered exercise/tax liability with 37,000 shares, increasing direct ownership by 62% to 164,250 units
- SEC Form EFFECT filed by IMAC Holdings Inc.
- SEC Form S-3/A filed by IMAC Holdings Inc. (Amendment)
- SEC Form S-3 filed by IMAC Holdings Inc.
- IMAC Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by IMAC Holdings Inc. (Amendment)
Latest NTRA
- SEC Form DEFA14A filed by Natera Inc.
- SEC Form DEF 14A filed by Natera Inc.
- SEC Form 4 filed by Sheena Jonathan
- William Blair initiated coverage on Natera
- Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
- SEC Form 3 filed by new insider Rubin Eric H
- Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
- SEC Form 4 filed by Rabinowitz Matthew
- 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform
- SEC Form 4 filed by Moshkevich Solomon